MGX · Insider Trading
Metagenomi Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by MGX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-11 | Laurence Reid | Director | Buy | +20,000 | +$23.40K |
| 2026-09-10 | Pamela Wapnick | Chief Financial Officer | Sell | −1,911 | −$2.21K |
| 2026-09-10 | Matthew Wein | See Remarks | Sell | −358 | −$415 |
| 2026-09-10 | Jian Irish | See Remarks | Sell | −2,140 | −$2.48K |
| 2026-06-11 | Eric Bjerkholt | Director | A | +21,000 deriv. | — |
| 2026-06-11 | Laurence Reid | Director | A | +17,400 deriv. | — |
| 2026-06-11 | Willard H Dere | Director | A | +21,000 deriv. | — |
| 2026-06-11 | Juergen Eckhardt | Director | A | +21,000 deriv. | — |
| 2026-06-10 | Matthew Wein | See Remarks | Sell | −558 | −$725 |
| 2026-06-10 | Pamela Wapnick | Chief Financial Officer | Sell | −2,884 | −$3.75K |
| 2026-06-10 | Jian Irish | See Remarks | Sell | −3,737 | −$4.85K |
| 2026-04-03 | Jian Irish | See Remarks | A | +46,000 | — |
| 2026-04-03 | Matthew Wein | See Remarks | A | +11,000 | — |
| 2026-04-03 | Pamela Wapnick | Chief Financial Officer | A | +24,000 | — |
| 2026-03-09 | Pamela Wapnick | Chief Financial Officer | Sell | −1,581 | −$2.53K |
| 2026-03-09 | Matthew Wein | See Remarks | Sell | −482 | −$771 |
| 2026-03-09 | Jian Irish | Chief Executive Officer | MIXED | −230,069 | −$2.57K |
| 2025-12-08 | Pamela Wapnick | Chief Financial Officer | Sell | −1,576 | −$2.79K |
| 2025-12-08 | Jian Irish | Chief Executive Officer | Sell | −1,602 | −$2.84K |
| 2025-12-08 | Matthew Wein | See Remarks | Sell | −199 | −$353 |
| 2025-12-08 | Brian C. Thomas | Director | Sell | −3,830 | −$6.79K |
| 2025-12-01 | Brian C. Thomas | Director | Sell | −2,701 | −$4.89K |
| 2025-12-01 | Pamela Wapnick | Chief Financial Officer | MIXED | +118,424 | +$189.15K |
| 2025-12-01 | Jian Irish | Chief Executive Officer | MIXED | +246,898 | +$394.70K |
| 2025-12-01 | Matthew Wein | See Remarks | MIXED | +95,801 | +$153.24K |
| 2025-09-02 | Laurence Reid | Director | A | +42,000 deriv. | — |
| 2025-06-12 | Juergen Eckhardt | Director | A | +21,000 deriv. | — |
| 2025-06-12 | Willard H Dere | Director | A | +21,000 deriv. | — |
| 2025-06-12 | Eric Bjerkholt | Director | A | +8,572 deriv. | — |
| 2025-06-09 | Matthew Wein | See Remarks | Sell | −199 | −$348 |
| 2025-06-09 | Pamela Wapnick | Chief Financial Officer | Sell | −1,576 | −$2.76K |
| 2025-06-09 | Sarah B. Noonberg | Chief Medical Officer | Sell | −5,239 | −$9.17K |
| 2025-06-09 | Jian Irish | See Remarks | Sell | −6,390 | −$11.18K |
| 2025-06-09 | Brian C. Thomas | Chief Executive Officer | Sell | −10,785 | −$18.87K |
| 2025-04-03 | Sarah B. Noonberg | Chief Medical Officer | A | +14,000 | — |
| 2025-04-03 | Jian Irish | See Remarks | A | +23,000 | — |
| 2025-04-03 | Pamela Wapnick | Chief Financial Officer | A | +14,000 | — |
| 2025-04-03 | Brian C. Thomas | Chief Executive Officer | A | +32,000 | — |
| 2025-04-03 | Matthew Wein | See Remarks | A | +7,425 | — |
| 2025-03-07 | Matthew Wein | See Remarks | Sell | −930 | −$1.74K |
| 2025-03-07 | Pamela Wapnick | Chief Financial Officer | Sell | −1,808 | −$3.39K |
| 2025-02-05 | Eric Bjerkholt | Director | A | +42,000 deriv. | — |
| 2024-12-06 | Pamela Wapnick | Chief Financial Officer | Sell | −1,559 | −$2.90K |
| 2024-09-06 | Pamela Wapnick | Chief Financial Officer | Sell | −6,265 | −$18.04K |
| 2024-04-03 | Willard H Dere | Director | A | +78,636 deriv. | — |
| 2024-04-03 | Sarah B. Noonberg | Chief Medical Officer | A | +57,763 | — |
| 2024-04-03 | Luis Borges | Chief Scientific Officer | A | +69,316 | — |
| 2024-04-03 | Sebastian Bernales | Director | A | +78,636 deriv. | — |
| 2024-04-03 | Simren Delaney | See Remarks | A | +6,931 | — |
| 2024-04-03 | Matthew Wein | See Remarks | A | +10,397 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Brian C. Thomas | Chief Executive Officer | 2,510,960 | $1.93M |
| Jian Irish | See Remarks | 668,107 | $512.71K |
| Pamela Wapnick | Chief Financial Officer | 206,580 | $158.53K |
| Matthew Wein | See Remarks | 126,133 | $96.79K |
| Sarah B. Noonberg | Chief Medical Officer | 109,135 | $83.75K |
| Laurence Reid | Director | 20,000 | $15.35K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MGX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.